In accordance to the requirement by the Indiana CTSI for core services, the following service policies are reviewed and approved by the Center for Medical Genomics advisory committee.
The center will not release samples to anyone except the owner: PI or active member of his/her lab. Data generated will be reviewed by personnel in the center for quality-control purposes. Data will only be sent to the PI or a person he/she designates. Permission from the PI is required for release of remaining samples or data.
The center will use quality-control information from all experiments to track performance of the center and to inform future client investigators about the usability of a set of samples. The center may ask for information regarding RNA or DNA yields from tissues and permission to use this information for guidance with other investigators.
Accounting requires quarterly reports on partially completed or unbilled experiments; the investigator’s name and status of project completeness will be provided. As a CTSI core, the IU School of Medicine Center for Medical Genomics is required to provide the name and department of investigators making use of the core and a list of publications resulting from core use. The Indiana Genomics Initiative (INGEN) also requires this type of information for biannual reports.
The Core Director will discuss all issues with the investigator in order to resolve them. Should issues (such as charge disputes, authorship and conflict of interest) arise that cannot be resolved in this manner, the Advisory Committee will assist in conflict resolution.
Current advisory committee members are: Dr. Howard J. Edenberg, Department of Biochemistry and Molecular Biology; Dr. Mark Gereci, Department of Medicine; and Dr. Milan Radovich, Department of Surgery.
The Center for Medical Genomics at IU School of Medicine expects payment for services rendered. An IU account number or a purchase order number should be provided at the beginning of the service. A full payment is expected if data is obtained regardless whether or not it represents the result expected by the investigator.
Center staff examines Quality Control at several steps in the process and will stop the process if yields or quality are not sufficient to continue. At this point the center will consult with the investigator to see how (s)he wants to proceed. Partial payment will be required to recover the costs associated with terminated experiments. Guidelines for sample submission include quality-control information. If quality-control guidelines are not met and the investigator wishes to have the center process the samples anyway, best efforts will be made; but even if the samples fail, payment is expected.
Work is generally completed on a first-come first-served basis. Minor rearrangements may be made when reagents or supplies are backordered from suppliers or if a minor shift in schedule can make better use of the equipment. The center reserves the right to break up larger experiments (> 32 arrays) if it can make better use of the equipment and allow center staff to minimize delays to small experiments. Delays can happen when the equipment fails. Customers will be notified if this occurs.
The IU School of Medicine Center for Medical Genomics should be acknowledged in all publications resulting from data generated by the Center, and a copy of the publication should be provided to the center so that reports required by the center’s oversight committee can be produced. Inclusion of center members as authors in publications is expected only when these individuals provide collaboration on experimental design and/or analysis and interpretation of the data. The re-charge mechanism does not preclude or replace authorship. If substantial intellectual contributions are required in experimental design, data analysis, interpretation and/or manuscript writing, co-authorship should be granted to the involved core personnel. This does not include providing a statement of the methods used.
“Microarray studies were carried out in the Center for Medical Genomics at Indiana University School of Medicine, which is partially supported by the Indiana Genomic Initiative at Indiana University (INGEN); INGEN is supported in part by the Lilly Endowment, Inc.”